Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Director Cyrus Taraporevala acquired 1,386.834 phantom stock units as deferred compensation, increasing his total beneficial ownership to 27,139.547 units.

Summary

• Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), acquired 1,386.834 phantom stock units.
• The transaction occurred on March 27, 2026, at a price of $27.04 per unit.
• These units represent deferred director's compensation, including dividend equivalents.
• Following this acquisition, Taraporevala beneficially owns a total of 27,139.547 phantom stock units.
• The units are settled in cash or common stock at the director's election upon retirement from the Board.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates a director's continued accumulation of company equity through a compensation plan, aligning their interests with shareholders.

Positives

• Director Cyrus Taraporevala increased his beneficial ownership in Pfizer through the acquisition of 1,386.834 phantom stock units.
• The acquisition is part of a deferred compensation plan, aligning director interests with long-term shareholder value.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of a historical insider transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions of company stock or stock equivalents as part of compensation, can signal management's confidence in the company's future prospects. This is a routine compensation event for a large pharmaceutical company like Pfizer.

Comparison to Industry Standards

• StockSavvy.ai observes that deferred compensation in the form of phantom stock units is a common practice among large, publicly traded companies, including those in the pharmaceutical sector like Johnson & Johnson or Merck, to align executive and director incentives with long-term shareholder value.
• The specific value and number of units are commensurate with director compensation packages at companies of Pfizer's size and market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: The transaction indicates a director's continued equity interest, potentially signaling confidence in the company's future.
• Directors: The deferred compensation plan provides a structured benefit for service on the board.

Next Steps

• The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it shows continued insider alignment, it does not present new material information that would warrant a change in investment recommendation. The transaction is an expected part of director remuneration and does not reflect a discretionary open-market purchase or sale that might signal a stronger sentiment.

Keywords

Pfizer, PFE, Cyrus Taraporevala, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Beneficial Ownership